Common Contracts
21 similar Exclusive Agency Agreement contracts by Cel Sci Corp, Cytrx Corp, Evoke Pharma Inc, others
STRICTLY CONFIDENTIAL CEL-SCI CorporationExclusive Agency Agreement • August 24th, 2017 • Cel Sci Corp • Biological products, (no disgnostic substances) • New York
STRICTLY CONFIDENTIALExclusive Agency Agreement • June 5th, 2017 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL Ms. Kathleen Valiasek Chief Financial Officer Amyris, Inc.Exclusive Agency Agreement • May 8th, 2017 • Amyris, Inc. • Industrial organic chemicals • New York
STRICTLY CONFIDENTIAL Alphatec Holdings, Inc.Exclusive Agency Agreement • March 23rd, 2017 • Alphatec Holdings, Inc. • Surgical & medical instruments & apparatus • New York
STRICTLY CONFIDENTIAL CEL-SCI CorporationExclusive Agency Agreement • March 10th, 2017 • Cel Sci Corp • Biological products, (no disgnostic substances) • New York
STRICTLY CONFIDENTIAL XTL Biopharmaceuticals Ltd.Exclusive Agency Agreement • February 22nd, 2017 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations • New York
STRICTLY CONFIDENTIAL CEL-SCI CorporationExclusive Agency Agreement • February 21st, 2017 • Cel Sci Corp • Biological products, (no disgnostic substances) • New York
January 13, 2017 STRICTLY CONFIDENTIAL Hemispherx BioPharma, Inc.Exclusive Agency Agreement • February 3rd, 2017 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York
December 12, 2016Exclusive Agency Agreement • December 14th, 2016 • Cytrx Corp • Biological products, (no disgnostic substances) • New York
This letter agreement (this “Agreement”) constitutes the agreement between CytRx Corporation (the “Company”) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”), that Rodman shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Rodman and nothing herein implies that Rodman would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Rodman’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Rodman deems appropriate under the circumstances and to the receipt of all internal approvals of Rodman in connection wi
STRICTLY CONFIDENTIAL Mr. Nadir Ali Chief Executive Officer Sysorex Global Holdings Corp.Exclusive Agency Agreement • December 12th, 2016 • Sysorex Global • Services-computer programming services • New York
September 24, 2016Exclusive Agency Agreement • September 27th, 2016 • BioPharmX Corp • Pharmaceutical preparations • New York
September 9, 2016Exclusive Agency Agreement • September 9th, 2016 • Cancer Genetics, Inc • Services-medical laboratories • New York
August 26, 2016 STRICTLY CONFIDENTIAL Hemispherx BioPharma, Inc.Exclusive Agency Agreement • September 1st, 2016 • Hemispherx Biopharma Inc • Biological products, (no disgnostic substances) • New York
STRICTLY CONFIDENTIAL Cel-Sci CorporationExclusive Agency Agreement • August 24th, 2016 • Cel Sci Corp • Biological products, (no disgnostic substances) • New York
June 24, 2016Exclusive Agency Agreement • August 9th, 2016 • Innovus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
July 29, 2016Exclusive Agency Agreement • August 1st, 2016 • Evoke Pharma Inc • Pharmaceutical preparations • New York
July 19, 2016Exclusive Agency Agreement • July 20th, 2016 • Evoke Pharma Inc • Pharmaceutical preparations • New York
July 14, 2016Exclusive Agency Agreement • July 15th, 2016 • Cytrx Corp • Biological products, (no disgnostic substances) • New York
This letter agreement (this “Agreement”) constitutes the agreement between CytRx Corporation (the “Company”) and Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC (“Rodman”), that Rodman shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Rodman and nothing herein implies that Rodman would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Rodman’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Rodman deems appropriate under the circumstances and to the receipt of all internal approvals of Rodman in connection wi
June 24, 2016 STRICTLY CONFIDENTIAL Stephen From President and Chief Executive Officer EyeGate Pharmaceuticals, Inc.Exclusive Agency Agreement • June 27th, 2016 • Eyegate Pharmaceuticals Inc • Pharmaceutical preparations • New York
May 15, 2016 STRICTLY CONFIDENTIAL Biostage, Inc.Exclusive Agency Agreement • May 16th, 2016 • Biostage, Inc. • Surgical & medical instruments & apparatus • New York
May 4, 2016Exclusive Agency Agreement • May 10th, 2016 • Genvec Inc • Pharmaceutical preparations • New York
